title: Reply to a. Avan et Al.
authors: Memorial Sloan Kettering Cancer Center, New York, NY baselgaj@mskcc.org.
authors: José
authors: J
authors: Baselga
authors: Roche Products, Welwyn Garden City, United Kingdom.
authors: Emma
authors: E
authors: Clark
authors: F. Hoffmann-La Roche, Basel, Switzerland.
authors: Astrid
authors: A
authors: Kiermaier
authors: Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC.
authors: Sandra M
authors: SM
authors: Swain
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases